Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. ERS Statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prenatal tobacco exposure and risk of asthma and allergy outcomes in childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. RAGE has potential pathogenetic and prognostic value in non-intubated hospitalized patients with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ERS Statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also having in vitro antiviral properties. This may improve outcomes in patients hospitalised for coronavirus disease 2019 (COVID-19).

METHODS: Placebo-controlled double-blind randomised multicentre trial. Patients aged ≥18 years, admitted to hospital for ≤48 h (not intensive care) with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription PCR test were recruited. The intervention was 500 mg daily azithromycin for 3 days followed by 250 mg daily azithromycin for 12 days combined with 200 mg twice-daily hydroxychloroquine for all 15 days. The control group received placebo/placebo. The primary outcome was days alive and discharged from hospital within 14 days (DAOH14).

RESULTS: After randomisation of 117 patients, at the first planned interim analysis, the data and safety monitoring board recommended stopping enrolment due to futility, based on pre-specified criteria. Consequently, the trial was terminated on 1 February 2021. 61 patients received the combined intervention and 56 patients received placebo. In the intervention group, patients had a median (interquartile range) 9.0 (3-11) DAOH14 versus 9.0 (7-10) DAOH14 in the placebo group (p=0.90). The primary safety outcome, death from all causes on day 30, occurred for one patient in the intervention group versus two patients receiving placebo (p=0.52), and readmittance or death within 30 days occurred for nine patients in the intervention group versus six patients receiving placebo (p=0.57).

CONCLUSIONS: The combination of azithromycin and hydroxychloroquine did not improve survival or length of hospitalisation in patients with COVID-19.

Original languageEnglish
Article number2100752
JournalThe European respiratory journal
Volume59
Issue number1
Pages (from-to)1-12
Number of pages12
ISSN0903-1936
DOIs
Publication statusPublished - Jan 2022

Bibliographical note

Copyright ©The authors 2022.

    Research areas

  • Adolescent, Adult, Azithromycin, COVID-19/drug therapy, Double-Blind Method, Humans, Hydroxychloroquine, SARS-CoV-2, Treatment Outcome

ID: 70609507